v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash flows used in operating activities:      
Net loss $ (7,380,536) $ (9,381,496) $ (21,462,588)
Fair value adjustment to convertible notes payable     1,250,000
Change in fair value of warrant liability (77,237) (77,237) 12,784,329
Stock based compensation 496,724 764,007  
Forgiveness of trade payable (416,000) (416,000)  
Financing expense     275,000
Amortization of intangibles 78,032 104,043 104,043
Increase in accrued interest and financing expense 402,411 714,081 696,799
Unrealized gain and accrued interest on investments (12,079) (93,779)  
Changes in assets and liabilities:      
Increase in accounts payable and accrued expenses (148,493) (217,806) 1,347,801
Decrease in prepaid expenses & other assets 518,788 123,455 (715,474)
Net cash used in operating activities (6,538,390) (8,480,732) (5,720,090)
Cash flows used in investing activities:      
Purchase of investments (9,899,121) (9,899,121)  
Payment for license acquisition (250,000) (250,000) (625,000)
Net cash used in investing activities (10,149,121) (10,149,121) (625,000)
Cash flows provided by financing activities:      
Payments of offering costs     141,338
Payments of deferred loan costs   42,045 (50,000)
Increase in due to officers     139,285
Payment of amounts due to officers (449,999) (599,999) (304,466)
Proceeds from issuance of "Bridge Notes", net     3,475,000
Payment of interest on "Bridge Notes"   (311,670)  
Proceeds from sale of equity securities, net 14,904,569 14,877,332 10,102,874
Net cash provided by financing activities 14,454,570 14,007,708 13,504,031
Net change in cash and cash equivalents: (2,232,941) (4,622,145) 7,158,941
Cash and cash equivalents - beginning of period 7,482,773 7,482,773 323,832
Cash and cash equivalents - end of period 5,249,832 2,860,628 7,482,773
Supplemental information - Non cash items:      
Interest paid     393,611
Exchange of "2020 Notes" for Ordinary shares     1,213,313
Exchange of "Bridge Notes" for Ordinary shares     5,000,000
Reclassification of warrant liability to equity upon issuance of "Exchange warrants" 296,362 296,362 $ 12,410,730
Deemed dividend on warrant modification 65,266 65,266  
Offering expenses associated with warrant modification 491,601 491,601  
Settlement of accrued expenses $ 193,537 $ 193,537